Literature DB >> 18629639

Body mass index and the efficacy of acid-mediating agents for GERD.

Brian C Jacobson1.   

Abstract

In studies of the association between obesity and gastroesophageal reflux, one subject that has received very little attention is the effect excess body mass may have on the effectiveness of acid-mediating agents. The lack of systematic research may reflect the perceived high clinical efficacy of drugs like proton pump inhibitors. Both proton pump inhibitors and histamine type 2 receptor antagonists have low rates of significant adverse events; if there are differences in the side effect profiles based on BMI, it is unlikely such associations would be detected. Also, while the metabolism of many drugs can be affected by body mass, it is not clear that such a relationship exists with acid-mediating agents. Nevertheless, there is evidence that body mass index may indeed be associated with the efficacy of proton pump inhibitors and histamine type 2 receptor antagonists. This review will examine that evidence and consider some of the possible pharmacokinetic effects that might relate to body mass index.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629639     DOI: 10.1007/s10620-008-0414-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

Review 1.  Pharmacokinetic considerations in obesity.

Authors:  R A Blouin; G W Warren
Journal:  J Pharm Sci       Date:  1999-01       Impact factor: 3.534

2.  Body-mass index and symptoms of gastroesophageal reflux in women.

Authors:  Brian C Jacobson; Samuel C Somers; Charles S Fuchs; Ciarán P Kelly; Carlos A Camargo
Journal:  N Engl J Med       Date:  2006-06-01       Impact factor: 91.245

3.  Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.

Authors:  Peter J Kahrilas; Philip Miner; John Johanson; Lian Mao; Leonard Jokubaitis; Sheldon Sloan
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

4.  Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr.

Authors:  G T Lesser; S Deutsch
Journal:  J Appl Physiol       Date:  1967-11       Impact factor: 3.531

5.  Association of obesity with hiatal hernia and esophagitis.

Authors:  L J Wilson; W Ma; B I Hirschowitz
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

6.  Pharmacokinetics of ranitidine in morbidly obese women.

Authors:  R L Davis; R W Quenzer; H P Bozigian; C W Warner
Journal:  DICP       Date:  1990-11

7.  Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.

Authors:  F Pace; V Annese; A Prada; A Zambelli; S Casalini; P Nardini; G Bianchi Porro
Journal:  Dig Liver Dis       Date:  2005-10       Impact factor: 4.088

Review 8.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

10.  Drug metabolism in diabetic subjects with fatty livers.

Authors:  H I Pirttiaho; P I Salmela; E A Sotaniemi; R O Pelkonen; U Pitkänen; P V Luoma
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

View more
  2 in total

1.  Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.

Authors:  Kafia Belhocine; Fabienne Vavasseur; Christelle Volteau; Laurent Flet; Yann Touchefeu; Stanislas Bruley des Varannes
Journal:  BMC Gastroenterol       Date:  2014-07-15       Impact factor: 3.067

2.  The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

Authors:  D A Peura; B Pilmer; B Hunt; R Mody; M C Perez
Journal:  Aliment Pharmacol Ther       Date:  2013-03-04       Impact factor: 8.171

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.